Evelyn Hsieh1, Michael T Yin2. 1. Section of Rheumatology, Yale School of Medicine, 300 Cedar Street, TAC S-525, PO Box 208031, New Haven, CT, 06517, USA. evelyn.hsieh@yale.edu. 2. Division of Infectious Diseases, Columbia University Medical Center, New York, NY, USA.
Abstract
PURPOSE OF REVIEW: Vitamin D (VitD) deficiency is highly prevalent among HIV-infected individuals. Given the overlapping risk for several chronic disease and immunomodulatory outcomes from both long-standing HIV and VitD deficiency, there is great interest in clarifying the clinical role of VitD for this population. RECENT FINDINGS: Recent studies have expanded our knowledge regarding the epidemiology and mechanisms of VitD deficiency-associated outcomes in the setting of HIV. Clinical trials focusing on VitD supplementation have demonstrated a positive impact on bone mineral density in subgroups of HIV-infected individuals initiating ART or on suppressive ART regimens; however, significant heterogeneity exists between studies and data are less consistent with other clinical outcomes. Further research is needed to clarify uncertainly in several domains, including identifying patients at greatest risk for poor outcomes from VitD deficiency, standardizing definitions and measurement techniques, and better quantifying the benefits and risks of VitD supplementation across different demographic strata for skeletal and extra-skeletal outcomes.
PURPOSE OF REVIEW: Vitamin D (VitD) deficiency is highly prevalent among HIV-infected individuals. Given the overlapping risk for several chronic disease and immunomodulatory outcomes from both long-standing HIV and VitD deficiency, there is great interest in clarifying the clinical role of VitD for this population. RECENT FINDINGS: Recent studies have expanded our knowledge regarding the epidemiology and mechanisms of VitD deficiency-associated outcomes in the setting of HIV. Clinical trials focusing on VitD supplementation have demonstrated a positive impact on bone mineral density in subgroups of HIV-infected individuals initiating ART or on suppressive ART regimens; however, significant heterogeneity exists between studies and data are less consistent with other clinical outcomes. Further research is needed to clarify uncertainly in several domains, including identifying patients at greatest risk for poor outcomes from VitD deficiency, standardizing definitions and measurement techniques, and better quantifying the benefits and risks of VitD supplementation across different demographic strata for skeletal and extra-skeletal outcomes.
Authors: Peter L Havens; Jennifer J Kiser; Charles B Stephensen; Rohan Hazra; Patricia M Flynn; Craig M Wilson; Brandy Rutledge; James Bethel; Cynthia G Pan; Leslie R Woodhouse; Marta D Van Loan; Nancy Liu; Jorge Lujan-Zilbermann; Alyne Baker; Bill G Kapogiannis; Catherine M Gordon; Kathleen Mulligan Journal: Antimicrob Agents Chemother Date: 2013-09-03 Impact factor: 5.191
Authors: Mario Cozzolino; Marcos Vidal; Maria Vittoria Arcidiacono; Pablo Tebas; Kevin E Yarasheski; Adriana S Dusso Journal: AIDS Date: 2003-03-07 Impact factor: 4.177
Authors: Kristin Holvik; Luai A Ahmed; Siri Forsmo; Clara G Gjesdal; Guri Grimnes; Sven Ove Samuelsen; Berit Schei; Rune Blomhoff; Grethe S Tell; Haakon E Meyer Journal: J Clin Endocrinol Metab Date: 2013-05-15 Impact factor: 5.958
Authors: Sunghee Lee; Vasudha Ahuja; Kamal Masaki; Rhobert W Evans; Emma J M Barinas-Mitchell; Hirotsugu Ueshima; Chol Shin; Jina Choo; Lauren Hassen; Daniel Edmundowicz; Lewis H Kuller; Bradley Willcox; Akira Sekikawa Journal: J Am Coll Nutr Date: 2016-06-17 Impact factor: 3.169
Authors: Christopher R Sudfeld; Molin Wang; Said Aboud; Edward L Giovannucci; Ferdinand M Mugusi; Wafaie W Fawzi Journal: PLoS One Date: 2012-06-29 Impact factor: 3.240
Authors: Nath Zungsontiporn; Raquel R Tello; Guangxiang Zhang; Brooks I Mitchell; Matthew Budoff; Kalpana J Kallianpur; Beau K Nakamoto; Sheila M Keating; Philip J Norris; Lishomwa C Ndhlovu; Scott A Souza; Cecilia M Shikuma; Dominic C Chow Journal: PLoS One Date: 2016-02-11 Impact factor: 3.240
Authors: Jane A Cauley; Neeta Parimi; Kristine E Ensrud; Douglas C Bauer; Peggy M Cawthon; Steven R Cummings; Andrew R Hoffman; James M Shikany; Elizabeth Barrett-Connor; Eric Orwoll Journal: J Bone Miner Res Date: 2010-03 Impact factor: 6.741
Authors: Phumla Zuleika Sinxadi; Helen Margaret McIlleron; Joel Alex Dave; Peter John Smith; Naomi Sharlene Levitt; David William Haas; Gary Maartens Journal: Medicine (Baltimore) Date: 2016-01 Impact factor: 1.817
Authors: Lediya T Cheru; Charles F Saylor; Kathleen V Fitch; Sara E Looby; Michael Lu; Udo Hoffmann; Takara L Stanley; Janet Lo Journal: Antivir Ther Date: 2019
Authors: Arnold Z Olali; Kelsey A Carpenter; Maria Myers; Anjali Sharma; Michael T Yin; Lena Al-Harthi; Ryan D Ross Journal: Curr HIV/AIDS Rep Date: 2022-06-20 Impact factor: 5.495
Authors: Matteo Bonato; Filippo Turrini; Laura Galli; Giuseppe Banfi; Paola Cinque Journal: Int J Environ Res Public Health Date: 2020-02-17 Impact factor: 3.390